C50.9 C81.9
Conditions
Interventions
Group 1: 25 patients with breast cancer who receive an Epirubicin-based chemotherapy and who show cardiotoxic side-effects will be investigated by young CMR techniques (T1- and T2-Mapping, Feature Tra
Sponsors
Uniklinik KölnInstitut für Diagnostische und Interventionelle Radiologie
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with breast cancer and epirubicin-based chemotherapy with manifest chemotherapy-induced cardiomyopathy; patients with breast cancer and epirubicin-based chemotherapy without manifest chemotherapy-induced cardiomyopathy; patients with Hodgkin lymphoma before chemotherapy and / or mediastinal radiation therapy
Exclusion criteria
Exclusion criteria: MR contraindications (pacemakers, insulin pumps, artificial heart valves, cochlear implants, etc.); indication for a high-urgent treatment of cancer; known (not therapy-associated) heart diseases and manifest, hemodynamically relevant heart insufficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| After acquisition of CMR data, all data (T1, T2, myocardial Strain, late enhancement, volumetric analyses) will be quantified by using various softwares. All data will be compared to the group of healthy volunteers. | — |
Countries
Germany
Contacts
Public ContactBettina Baeßler
Uniklinik Köln, Institut für Diagnostische und Interventionelle Radiologie
Outcome results
None listed